Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit
By Bryan Koenig · August 28, 2024, 7:33 PM EDT
Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login